Aveo: Tivozanib Patients Up To 5X More Likely To Have PFS Vs. Nexavar In Kidney Cancer

 Aveo Pharmaceuticals Inc 

AVEO +4.86%

 (Get Free Alerts for AVEO) will present new long-term progression-free survival (PFS) data from the Phase 3 TIVO-3 study in kidney cancer at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.

• The trial is evaluating Fotivda (tivozanib) to Bayer AG's 
  BAYRY +2.88%
   (Get Free Alerts for BAYRY) Nexavar (sorafenib) in advanced renal cell carcinoma (RCC) patients following two or more prior systemic therapies.
• "This marks the first presentation of five-year follow-up data for patients being treated in the third- or fourth-line RCC setting and helps guide clinical treatment," said Michael Bailey, President, and CEO.
• Landmark five-year follow-up data show PFS rates are consistently higher with Fotivda vs. sorafenib, with 12% vs. 2% and 8% vs. 0% at three and four years, respectively. 
• Long-term PFS represents a clinically meaningful outcome for patients in the third- and fourth-line treatment setting.
• Long-term overall survival was also analyzed, and a non-significant trend favoring Fotivda continued to emerge with the accumulation of events (HR, 0.89).

https://www.benzinga.com/general/biotech/22/02/25634534/aveo-says-tivozanib-patients-up-to-5x-more-likely-to-experience-long-term-pfs-vs-nexavar-in-kidne